{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=92",
    "query": {
      "condition": "Plasma",
      "page": 92
    },
    "page_size": 10
  },
  "pagination": {
    "page": 92,
    "page_size": 10,
    "total_count": 3601,
    "total_pages": 361,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=93&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=91&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T12:55:28.544Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01502085",
      "title": "Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Vorinostat, Lenalinomide and Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2011-12",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502085"
    },
    {
      "nct_id": "NCT01929720",
      "title": "Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anxiety Disorder",
        "Worry",
        "Uncertainty",
        "Sleep Disorders",
        "Insomnia",
        "Fatigue",
        "Pain",
        "Depression",
        "Cognitive-behavioral Therapy",
        "Psychological Intervention",
        "Esophageal Cancer",
        "Pancreatic Cancer",
        "Leukemia",
        "Lung Cancer",
        "Multiple Myeloma",
        "Ovarian Neoplasm",
        "Stage III or IV Cervical or Uterine Cancer",
        "Stage IIIB, IIIC, or IV Breast Cancer",
        "Glioblastoma Multiforme",
        "Relapsed Lymphoma",
        "Stage III or IV Colorectal Cancer",
        "Stage IIIC or IV Melanoma"
      ],
      "interventions": [
        {
          "name": "Cognitive-behavioral therapy for worry, uncertainty & insomnia",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2011-08",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929720"
    },
    {
      "nct_id": "NCT05546723",
      "title": "LMY-920 for Treatment of Relapsed or Refractory Myeloma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma, Refractory",
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "Autologous CAR-T cell therapy expressing the BAFF-ligand.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Luminary Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-03-13",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-18",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05546723"
    },
    {
      "nct_id": "NCT03678259",
      "title": "124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Systemic Amyloidosis"
      ],
      "interventions": [
        {
          "name": "124I-p5+14 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-10-01",
      "completion_date": "2021-10-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03678259"
    },
    {
      "nct_id": "NCT02114827",
      "title": "Efficacy of a Patient Education Video",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Leukemia, Not Otherwise Specified",
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Video",
          "type": "BEHAVIORAL"
        },
        {
          "name": "FAQ Sheet",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2014-04",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-07-21",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02114827"
    },
    {
      "nct_id": "NCT07756242",
      "title": "Pharmacokinetic Study of Therapeutic Plasma Exchange",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune-related Adverse Event"
      ],
      "interventions": [
        {
          "name": "Spectra Optia Apheresis System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756242"
    },
    {
      "nct_id": "NCT01056276",
      "title": "Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2010-05",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2017-05-03",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 13,
      "location_summary": "Thousand Oaks, California • Fort Myers, Florida • Baton Rouge, Louisiana + 9 more",
      "locations": [
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01056276"
    },
    {
      "nct_id": "NCT06615479",
      "title": "A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma (RRMM)"
      ],
      "interventions": [
        {
          "name": "BMS-986393",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2025-03-12",
      "completion_date": "2032-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06615479"
    },
    {
      "nct_id": "NCT03601078",
      "title": "An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "bb2121",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalomide",
          "type": "DRUG"
        },
        {
          "name": "Talquetamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "2018-12-13",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601078"
    },
    {
      "nct_id": "NCT01148108",
      "title": "Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma",
        "B Cell Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Canfosfamide HCl for injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telik",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2010-06",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-03-15",
      "last_synced_at": "2026-11-19T12:55:28.544Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01148108"
    }
  ]
}